Canada markets closed

Immix Biopharma, Inc. (IMMX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.1800+0.1300 (+6.34%)
At close: 04:00PM EDT
2.2500 +0.07 (+3.21%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.0500
Open2.0300
Bid2.1600 x 300
Ask2.2100 x 400
Day's Range1.9601 - 2.2100
52 Week Range1.5500 - 7.7500
Volume220,354
Avg. Volume143,942
Market Cap57.583M
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.9900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • GlobeNewswire

    Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

    Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the 1st patient has been dosed at MSKCC

  • Simply Wall St.

    Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • GlobeNewswire

    Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

    LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it will present and host institutional investor meetings at the Stifel 2024 Cell Therapy Forum. Stifel 2024 Cell Therapy Forum - Immix Biopharma Date:Tuesday, July 9, 2024Presentation: Immix Biopharma to presentLocation:VirtualInvestor Meetings:The IMMX Team will be